Compare DMRC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | STXS |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 190.6M |
| IPO Year | 2008 | 2004 |
| Metric | DMRC | STXS |
|---|---|---|
| Price | $9.48 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | 276.6K | ★ 345.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.58 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | $25,213,000.00 | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $1.70 |
| 52 Week High | $17.47 | $3.59 |
| Indicator | DMRC | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 50.95 |
| Support Level | $9.52 | $1.74 |
| Resistance Level | $10.31 | $1.99 |
| Average True Range (ATR) | 1.26 | 0.09 |
| MACD | -0.68 | -0.00 |
| Stochastic Oscillator | 3.78 | 52.00 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.